Cocaine-Induced Dopamine Transporter Changes are Reversed by Amphetamine
安非他明可逆转可卡因引起的多巴胺转运蛋白变化
基本信息
- 批准号:8825902
- 负责人:
- 金额:$ 4.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-15 至 2017-08-14
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAmphetaminesAnimal TestingAnimalsAutomobile DrivingBasic ScienceBehavioralBolus InfusionBrainCharacteristicsChemical StructureChronicCocaineCocaine DependenceDataDopamineDoseGoldHealthHourHumanIndividual DifferencesInfusion proceduresInjection of therapeutic agentIntakeKineticsLiteratureLocomotionMeasurementMeasuresMethamphetamineMethylphenidateModelingMotivationNeurobiologyNomifensineNucleus AccumbensOutcomePharmaceutical PreparationsPharmacodynamicsPharmacological TreatmentPharmacologyPharmacotherapyRattusRecording of previous eventsResearchRodentRodent ModelSalineScheduleSelf AdministrationSliceTherapeutic EffectTimeUnited Statesaddictionbasebehavior measurementcocaine exposurecocaine usedesigndopamine transporterinhibitor/antagonistinterestmeetingsneurochemistrypresynapticpublic health relevanceresearch studyresponsereverse toleranceuptake
项目摘要
DESCRIPTION (provided by applicant): Cocaine (COC) dependence in the United States is a major health problem that currently has no approved pharmacological therapies to help in treatment. The "gold standard" of rodent models used in addiction research is COC self-administration. We have used this model to show that extended exposure to COC results in a pharmacodynamic tolerance of the dopamine transporter (DAT). Tolerance of the DAT to COC is a relatively new phenomenon discovered by our lab, which opened up a new avenue of research into the manipulation of COC tolerance, which we will explore in this proposal. We found that administration of a single AMPH bolus (0.56 mg/kg IV) rapidly and completely reversed the COC tolerance at the DAT, and even caused COC potency to increase above control levels. The specific aims include experiments that characterize and expand on this discovery. In Specific Aim 1 we will explore the lowest effective dose of AMPH that can cause a reversal of DAT plasticity and the time course of this effect. Although this characterization is quite important, we are primarily interested in discovering the structural and functional changes in the DAT that are responsible for this effect. Thus, for Specific Aim 2, we will use structurally
different DA releasers and blockers with different DAT affinities in place of an AMPH bolus and use slice voltammetry to explore COC potency and presynaptic DA function (release and uptake) in response to these compounds. Additionally, we are interested in the behavioral implications for our neurochemical data. In Specific Aim 3 we will test animals before and after self-administration and an AMPH bolus with locomotor assessments while another group will be assessed on a progressive ratio schedule of COC self-administration. While our interest is primarily in the basic pharmacology driving the DAT changes, this may be relevant to the literature proposing DAT releasers such as AMPH as putative COC addiction pharmacotherapies. Although agonist therapies for COC addiction are controversial, we may be able to define a putative mechanism for some of their therapeutic effects which could potentially drive more rationale design of such therapies.
描述(由申请人提供):在美国,可卡因(COC)依赖是一个主要的健康问题,目前还没有批准的药物治疗来帮助治疗。成瘾研究中使用的啮齿动物模型的“黄金标准”是COC自我给药。我们已经使用该模型表明,长期暴露于COC导致多巴胺转运蛋白(DAT)的药效学耐受性。DAT对COC的耐受性是我们实验室发现的一个相对较新的现象,这为COC耐受性的操纵开辟了一条新的研究途径,我们将在本提案中进行探索。我们发现,单次注射AMPH(0.56 mg/kg IV)可迅速并完全逆转DAT时的COC耐受性,甚至导致COC效力增加至对照水平以上。具体目标包括表征和扩展这一发现的实验。在具体目标1中,我们将探索AMPH的最低有效剂量,可导致DAT可塑性逆转以及这种作用的时间过程。虽然这种表征是非常重要的,我们主要感兴趣的是发现DAT的结构和功能的变化,负责这种效果。因此,对于具体目标2,我们将在结构上使用
不同的DA释放剂和具有不同DAT亲和力的阻断剂代替AMPH推注,并使用切片伏安法来探索COC效力和突触前DA功能(释放和摄取)对这些化合物的响应。此外,我们感兴趣的是我们的神经化学数据的行为含义。在具体目标3中,我们将在自我给药和AMPH推注前后对动物进行测试,并进行运动评估,而另一组将按照COC自我给药的渐进比例方案进行评估。 虽然我们的兴趣主要是在基本药理学驱动DAT的变化,这可能是相关的文献提出DAT释放剂,如AMPH作为假定的COC成瘾药物治疗。 尽管COC成瘾的激动剂疗法存在争议,但我们可能能够定义其某些治疗作用的假定机制,这可能会推动此类疗法的更多合理设计。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jamie Hannah Rose其他文献
Jamie Hannah Rose的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jamie Hannah Rose', 18)}}的其他基金
Cocaine-Induced Dopamine Transporter Changes are Reversed by Amphetamine
安非他明可逆转可卡因引起的多巴胺转运蛋白变化
- 批准号:
8895292 - 财政年份:2013
- 资助金额:
$ 4.27万 - 项目类别:
Cocaine-Induced Dopamine Transporter Changes are Reversed by Amphetamine
安非他明可逆转可卡因引起的多巴胺转运蛋白变化
- 批准号:
8526648 - 财政年份:2013
- 资助金额:
$ 4.27万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 4.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 4.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 4.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)